β遮断薬のすべて 第3版

出版社: 先端医学社
著者:
発行日: 2009-04-10
分野: 薬学  >  薬物学
ISBN: 9784884075484
電子書籍版: 2009-04-10 (第3版第1刷)
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,585 円(税込)

商品紹介

現在までに蓄積されたβ遮断薬に関する膨大な臨床成績とその周辺の循環器疾患領域の新知見を含めて解説。循環器科専門医のみならず臨床医、研修医においてβ遮断薬を理解するための一助となる書。

目次

  • 表紙
  • 第2版 序
  • 初版 序
  • 執筆者一覧
  • 目次
  • Part 1 β遮断薬のプロファイル
  • 1. β遮断薬の開発の歴史
  • はじめに
  • 1. 狭心症治療薬としてのβ遮断薬の開発とプロプラノロールの登場
  • 2. 副作用の軽減をめざしたβ遮断薬の開発―ISAを有するβ遮断薬ピンドロールの登場―
  • 3. β1選択性β遮断薬の開発と狭心症,高血圧より心不全への適応の拡大
  • 4. αβ遮断薬カルベジロールの開発と心不全における高い評価
  • おわりに
  • 2. β遮断薬の分類
  • はじめに
  • 1. β受容体の種類,分布,生理作用
  • 2. β遮断薬の分類とその作用
  • 1) β1受容体選択性
  • 2) α1受容体遮断作用
  • 3) ISA
  • 4) 血液脳関門通過性
  • 5) 新しい世代のβ遮断薬
  • おわりに
  • 3. β遮断薬の薬物動態
  • はじめに
  • 1. β受容体の分類と臓器分布
  • 2. β遮断薬の分類,作用
  • 3. β遮断薬の薬物動態
  • おわりに
  • Part 2 β遮断薬に関する最近の話題
  • 1. EBM時代におけるβ遮断薬の臨床応用
  • はじめに
  • 1. 降圧薬としてのβ遮断薬
  • 2. 虚血性心疾患に対するβ遮断薬
  • 3. 慢性心不全に対するβ遮断薬
  • 4. 不整脈治療におけるβ遮断薬
  • おわりに
  • 2. CV continuumにおけるβ遮断薬の役割
  • はじめに
  • 1. CV continuum
  • 2. β遮断薬の作用機序
  • 3. CV continuumとβ遮断薬のかかわり
  • 1) 心血管危険因子
  • 2) 心筋梗塞
  • 3) 左室リモデリング,慢性心不全
  • 4) 腎疾患
  • おわりに
  • 3. クラス・エフェクトを超えたβ遮断薬の薬理学的特徴を探る
  • はじめに
  • 1. 心不全患者におけるβ遮断薬の薬理作用別にみた効果の差異
  • 2. 心筋梗塞後患者におけるβ遮断薬の薬理作用別にみた効果の差異
  • 3. β遮断薬と新規糖尿病発症のリスク
  • 4. CKDにおけるβ遮断薬
  • おわりに
  • 4. わが国の医療経済においてβ遮断薬はどのような役割を果たすのか
  • はじめに
  • 1. 国民医療費における高血圧の位置づけ
  • 2. 医療経済を考えた高血圧治療におけるβ遮断薬の役割
  • 3. 心疾患治療におけるβ遮断薬の費用対効果
  • おわりに
  • 5. 各種高血圧ガイドラインにおけるβ遮断薬の位置づけ
  • はじめに
  • 1. 各国高血圧ガイドラインにおける第一選択薬
  • 2. WHOガイドラインと米国JNCガイドライン
  • 3. 欧州,英国,カナダガイドライン
  • 4. わが国のガイドラインJSH2009
  • 5. 併用療法での位置づけ
  • おわりに
  • 6. 最近の疫学および慢性心不全管理ガイドラインにおけるβ遮断薬の評価
  • はじめに
  • 1. 心不全症例に対するβ遮断薬処方の実際
  • 2. 呼吸器疾患合併症例へのβ遮断薬投与
  • 3. 高齢者に対する投与
  • 4. 慢性心不全管理ガイドラインにおけるβ遮断薬の評価
  • おわりに
  • Part 3 β遮断薬の各臓器への作用を探る
  • 1. β遮断薬の心筋に対する作用
  • はじめに
  • 1. 心臓に発現しているβアドレナリン受容体のサブタイプ
  • 2. βアドレナリン受容体のシグナル伝達
  • 3. βアドレナリン刺激に対する心臓の生物学・生理学的反応
  • 4. 心不全におけるβアドレナリン受容体シグナルの変化
  • 5. 遺伝子改変マウス
  • 6. 遺伝子多型
  • 7. β遮断薬の作用
  • おわりに
  • 2. β遮断薬の血管・血管内皮に対する作用
  • はじめに
  • 1. 内皮細胞に対する作用
  • 1) NO産生促進作用
  • 2. 平滑筋細胞に対する作用
  • 1) 血管トーヌスの調節作用
  • 3. 血管病変の形成過程に及ぼす影響
  • 1) 抗酸化作用
  • 2) 細胞増殖 / 血管リモデリングに及ぼす影響
  • 3) 動脈壁への脂質沈着抑制作用
  • 4) 動脈硬化に対する作用
  • おわりに
  • 3. β遮断薬の脳循環に対する作用
  • はじめに
  • 1. 脳卒中急性期, 悪性高血圧における脳循環動態に対するβ遮断薬の影響
  • 2. β遮断薬の脳保護作用について
  • 3. 脳卒中急性期免疫機能抑制状態への交感神経系の関与
  • おわりに
  • 4. β遮断薬の腎臓に対する作用
  • はじめに
  • 1. 腎障害とSNS
  • 2. CKD患者におけるβ遮断薬の使用状況
  • 3. CKDにおける心不全とβ遮断薬の効果
  • 4. β遮断薬による腎機能への影響
  • 5. アルブミン尿とCVDの関連―「strain vessel仮説」―
  • 6. GEMINI試験
  • 7. ビソプロロールによる腎保護作用機序
  • 8. 腎機能低下時におけるβ遮断薬の投与量
  • おわりに
  • Part 4 β遮断薬の糖・脂質代謝への影響をみる
  • 1. 糖代謝に対するβ遮断薬の影響
  • はじめに
  • 1. β遮断薬と糖代謝メカニズムの関係
  • 2. β遮断薬によるインスリン抵抗性の悪化・糖尿病発症のエビデンス
  • 3. 血管拡張性β遮断薬によるインスリン感受性および血糖コントロール改善のメカニズムおよびエビデンス
  • おわりに
  • 2. 脂質代謝・肥満に対するβ遮断薬の影響
  • はじめに
  • 1. 交感神経系と脂質代謝の関連性について
  • 2. β遮断薬の血清脂質・リポ蛋白に及ぼす影響
  • 3. β遮断薬の肥満・アデイポサイトカインに及ぼす影響
  • 1) β遮断薬の肥満に及ぼす影響
  • 2) β遮断薬のアデイポサイトカインに及ぼす影響
  • おわりに
  • 3. メタボリックシンドロームに対するβ遮断薬の影響
  • はじめに
  • 1. メタボリックシンドローム合併高血圧の治療
  • 1) 生活習慣の改善, 降圧目標
  • 2) 各種降圧薬のインスリン抵抗性への影響
  • 3) β遮断薬のインスリン抵抗性への影響
  • 4) カルベジロールのインスリン抵抗性への影響
  • おわりに
  • Part 5 β遮断薬の酸化ストレスへの効果を探る
  • 1. 高血圧における酸化ストレスとβ遮断薬
  • はじめに
  • 1. 酸化ストレスと高血圧における交感神経系
  • 2. β遮断薬の酸化ストレスへの効果
  • おわりに
  • 2. 心筋症における酸化ストレスとβ遮断薬
  • はじめに
  • 1. 心筋における酸素ストレス発生のメカニズム
  • 1) ミトコンドリアにおける活性酸素産生
  • 2) NADPHオキシダーゼ複合体
  • 3) キサンチンオキシダーゼ
  • 2. β受容体活性化による活性酸素の産生
  • 3. 活性酸素による細胞傷害とβ遮断薬による治療・予防効果
  • 1) 心筋線維化・心筋リモデリングに対する効果
  • 2) アポトーシス・細胞死に対する効果
  • 3) Ca2+ハンドリングに対する効果
  • おわりに
  • 3. 心不全における酸化ストレスとβ遮断薬
  • はじめに
  • 1. 心不全における酸化ストレスの関与
  • 2. 心不全における酸化ストレス増加の要因
  • 1) 交感神経活動・カテコールアミンの活性化
  • 2) レニン・アンジオテンシン(RA)系の活性化
  • 3) 炎症・免疫・サイトカインの活性化
  • 4) 頻拍
  • 5) 機械的負荷
  • 6) 虚血
  • 7) NADPHオキシダーゼの活性化
  • 8) ミトコンドリア機能不全
  • 9) eNOSアンカップリング
  • 10) 抗酸化酵素作用の低下
  • 3. β遮断薬による酸化ストレスの軽減作用
  • 1) 治療による酸化ストレス軽減
  • 2) 酸化ストレス軽減の機序
  • おわりに
  • Part 6 高血圧治療におけるβ遮断薬の有用性を探る
  • 1. β遮断薬の降圧作用と降圧効果
  • はじめに
  • 1. β遮断薬の降圧作用
  • 1) 心拍出量抑制
  • 2) レニン分泌抑制
  • 3) 中枢神経抑制
  • 4) 神経終末からのノルアドレナリン遊離の抑制
  • 5) 血管拡張性プロスタグランジン刺激
  • 6) 圧受容体リセッティング
  • 2. β遮断薬の降圧効果
  • おわりに
  • 2. 軽症高血圧におけるβ遮断薬の位置づけ
  • はじめに
  • 1. 軽症高血圧に対する治療戦略
  • 2. 軽症高血圧における薬物療法のEBM
  • 3. β遮断薬の位置づけ
  • 4. β遮断薬と血行動態
  • 5. β遮断薬の糖・脂質代謝への影響
  • おわりに
  • 3. 中等症,重症高血圧におけるβ遮断薬の位置づけ
  • はじめに
  • 1. 合併症を伴わない中等症,重症高血圧におけるβ遮断薬の位置づけ
  • 2. 冠動脈疾患合併高血圧例におけるβ遮断薬の位置づけ
  • 3. 心不全合併高血圧例におけるβ遮断薬の位置づけ
  • 4. 脳卒中合併高血圧例におけるβ遮断薬の位置づけ
  • 5. 糖尿病合併高血圧例におけるβ遮断薬の位置づけ
  • 6. 高齢者高血圧におけるβ遮断薬の位置づけ
  • おわりに
  • 4. 二次性高血圧とβ遮断薬
  • はじめに
  • 1. 従来の二次性高血圧とβ遮断薬
  • 1) 慢性腎臓病(CKD)
  • 2. 二次性高血圧として考えるインスリン抵抗性と関連した高血圧
  • 3. 妊娠に伴う高血圧について
  • おわりに
  • 5. 若年性高血圧とβ遮断薬
  • はじめに
  • 1. 若年性高血圧の病態生理と機序
  • 1) 若年性の高血圧の特徴
  • 2) 交感神経系とレニン・アンジオテンシン系
  • 2. 若年性高血圧の治療
  • 1) 非薬物治療
  • 2) 薬物治療
  • おわりに
  • 6. 高齢者高血圧とβ遮断薬
  • はじめに
  • 1. 高齢者高血圧の特徴とβ遮断薬
  • 2. 高齢者高血圧におけるβ遮断薬のエビデンス
  • 3. 大規模臨床試験の評価における問題点
  • 4. 高齢者高血圧のガイドライン
  • おわりに
  • 7. 併用療法におけるβ遮断薬の実際
  • はじめに
  • 1. 利尿薬との併用
  • 2. Ca拮抗薬との併用
  • 3. ACE阻害薬もしくはARBとの併用
  • おわりに
  • 8. 早朝高血圧,仮面高血圧とβ遮断薬
  • はじめに
  • 1. 早朝高血圧,仮面高血圧の心血管リスク
  • 2. 早朝高血圧,仮面高血圧に対するβ遮断薬の効果
  • 1) β遮断薬と薬理学的特徴
  • 2) β遮断薬を早朝高血圧改善に用いる
  • 3. JSH2009での心疾患をもつ高血圧患者への降圧目標
  • おわりに
  • Part 7 合併症を伴った高血圧とβ遮断薬の臨床応用を探る
  • 1. 虚血性心疾患を伴った高血圧とβ遮断薬
  • はじめに
  • 1. 虚血性心疾患の危険因子としての高血圧
  • 2. 虚血性心疾患の成因,病態とJカーブ現象
  • 3. 狭心症を合併する高血圧に対するβ遮断薬の適用
  • 4. 心筋梗塞を合併する高血圧に対するβ遮断薬の適用
  • おわりに
  • 2. 不整脈を伴った高血圧とβ遮断薬
  • はじめに
  • 1. 高血圧と不整脈
  • 1) 自律神経機能を介した影響
  • 2) 心肥大を介した影響
  • 2. 不整脈に対するβ遮断薬の適応
  • 1) 心室期外収縮
  • 2) 心房細動(Af)
  • 3) 心臓突然死
  • おわりに
  • 3. CKDを伴った高血圧とβ遮断薬
  • はじめに
  • 1. 腎臓の交感神経系支配と腎機能調節
  • 2. CKDの病態形成における交感神経系の役割
  • 1) CKDにおける交感神経系活性化のメカニズム
  • 2) CKDの病態形成における交感神経活性化の役割
  • 3. CKD診療におけるβ遮断薬の有用性
  • 1) β遮断薬の腎作用
  • 2) β遮断薬の腎保護作用
  • 3) カルベジロールの腎保護作用のメカニズム
  • 4) 心・腎連関の視点からみたβ遮断薬の有用性
  • おわりに
  • 4. 脳血管障害を伴った高血圧とβ遮断薬
  • はじめに
  • 1. β遮断薬の基礎
  • 2. β遮断薬の脳循環に対する作用
  • 3. 脳血管障害の一次予防におけるβ遮断薬の役割
  • 4. 脳血管障害急性期の血圧管理
  • 5. 脳血管障害慢性期の血圧管理
  • 6. β遮断薬カルベジロールの脳保護効果
  • 7. β遮断薬の動脈硬化抑制作用
  • おわりに
  • 5. 糖尿病を伴った高血圧とβ遮断薬
  • はじめに
  • 1. 糖尿病を伴った高血圧におけるβ遮断薬の位置づけ
  • 2. β遮断薬のインスリン抵抗性・糖代謝に及ぼす影響
  • 3. β遮断薬と低血糖
  • 4. 糖尿病患者におけるβ遮断薬のエビデンス
  • 1) β遮断薬と他剤との比較
  • 2) 虚血性心疾患がある場合のエビデンス
  • おわりに
  • 6. 脂質異常症・動脈硬化を伴った高血圧とβ遮断薬
  • はじめに
  • 1. β遮断薬の脂質代謝に及ぼす影響
  • 2. β遮断薬の抗動脈硬化作用
  • 1) β遮断薬の抗酸化作用
  • 2) β遮断薬の抗粥腫(プラーク) 作用
  • 3) 血管拡張作用
  • 3. 動脈硬化を伴った高血圧治療
  • 1) 虚血性心疾患
  • 2) 大動脈瘤
  • おわりに
  • 7. ストレス性高血圧とβ遮断薬
  • はじめに
  • 1. ストレスと血圧
  • 2. ストレス性血圧反応の評価
  • 3. ストレス性高血圧に対する対処とβ遮断薬
  • おわりに
  • Part 8 虚血性心疾患治療薬としてのβ遮断薬の有用性をみる
  • 1. 虚血性心疾患治療薬としてのβ遮断薬の作用機序
  • はじめに
  • 1. 冠循環調節機構
  • 1) 冠血管トーヌスの自律神経性調節
  • 2) 冠血管トーヌスの体液・代謝性調節
  • 2. β遮断薬の薬理作用
  • 3. β遮断薬の種類と特徴
  • 1) β1選択性
  • 2) 内因性交感神経刺激作用(ISA)
  • 3) 膜安定化作用(MSA)
  • 4) 脂溶性または水溶性
  • 5) α遮断作用
  • 6) その他の血管拡張作用
  • 7) 抗酸化作用
  • 4. 虚血性心疾患治療薬としてのβ遮断薬の作用機序
  • 1) 狭心症治療薬としてのβ遮断薬の作用機序
  • 2) 心筋梗塞治療薬としてのβ遮断薬の作用機序
  • 3) β遮断薬の副作用―冠攣縮―
  • おわりに
  • 2. 心筋梗塞急性期治療薬としてのβ遮断薬
  • はじめに
  • 1. 過去の代表的な臨床試験
  • 1) ISIS-1
  • 2)MIAMI
  • 3)TIMI II B
  • 2. AHAガイドラインの内容と注意点
  • 3. リスク・ベネフィットを考えた適応の重要性
  • おわりに
  • 3. 心筋梗塞慢性期治療薬としてのβ遮断薬
  • はじめに
  • 1. 抗虚血作用
  • 1) 抗虚血作用に関する基礎的検討
  • 2) 臨床における心筋梗塞二次予防効果
  • 2. 抗不整脈作用
  • 1) カテコールアミンの催不整脈作用とβ遮断薬の影響
  • 2) 臨床における抗不整脈効果
  • 3. 左室リモデリングに対する効果
  • 4. β遮断薬投与の問題点
  • おわりに
  • 4. 狭心症治療薬としてのβ遮断薬
  • はじめに
  • 1. 慢性安定型狭心症とβ遮断薬
  • 2. 従来からのβ遮断薬
  • 3. 新しいβ遮断薬
  • 4. 日本人の狭心症とβ遮断薬
  • おわりに
  • 5. 無症候性心筋虚血とβ遮断薬
  • はじめに
  • 1. 無症候性心筋虚血の分類とその頻度
  • 2. 無症候性心筋虚血の病態・エビデンスを考慮した薬物治療
  • 3. 無症候性心筋虚血の長期予防効果と予後
  • おわりに
  • 6. 抗癌剤による心筋症とβ遮断薬
  • はじめに
  • 1. ドキソルビシンによる心筋症
  • 2. ドキソルビシンによる心筋症とβ遮断薬
  • 3. トラスツズマブによる心筋症
  • 4. トラスツズマブによる心筋症とβ遮断薬
  • 5. ベバシズマブによる心筋症
  • 6. ベバシズマブによる心筋症とβ遮断薬
  • おわりに
  • Part 9 不整脈治療薬としてのβ遮断薬の臨床応用をみる
  • 1. 不整脈治療薬としてのβ遮断薬の作用機転と選択基準
  • はじめに
  • 1. 不整脈治療において考慮されるべき作用
  • 2. β遮断薬の電気生理学的作用機転
  • 3. 不整脈治療薬としてのβ遮断薬の効果
  • 4. 不整脈治療に適したβ遮断薬の選択
  • おわりに
  • 2. 不整脈におけるβ遮断薬の位置づけと使用法
  • はじめに
  • 1. 基礎心疾患を伴わない例
  • 1) 期外収縮
  • 2) 上室頻拍
  • 3) 心房細動・粗動
  • 4) 心室頻拍・細動
  • 2. 基礎心疾患を伴う場合
  • 1) 心筋梗塞例
  • 2) 心不全例
  • 3) 突然死蘇生例
  • 4) QT延長症候群(LQT)
  • おわりに
  • Part 10 突然死の予防とβ遮断薬
  • 1. 突然死の予防とβ遮断薬
  • はじめに
  • 1. 急性心筋梗塞後症例におけるβ遮断薬の突然死予防
  • 2. 心不全症例におけるβ遮断薬の突然死予防
  • おわりに
  • Part 11 心不全治療薬としてのβ遮断薬の有用性を探る
  • 1. 慢性心不全に関する大規模臨床試験からみたβ遮断薬の評価
  • はじめに
  • 1. 大規模臨床試験からみたβ遮断薬
  • 2. ACE阻害薬とβ遮断薬
  • 3. β遮断薬はクラス・エフェクトか?
  • 4. ガイドラインでの位置づけ
  • おわりに
  • 2. β遮断薬のリバース・リモデリング
  • はじめに
  • 1. 左室リモデリングとは
  • 2. 心臓交感神経活性の亢進と左室リモデリング
  • 3. β遮断薬による左室リモデリングの抑制
  • 4. 遮断薬による左室のリバース・リモデリングの機序
  • 5. リバース・リモデリングは予後改善の原因なのか?
  • 6. 心機能改善のレスポンダーとノンレスポンダー
  • おわりに
  • 3. 心不全におけるβ遮断薬の有効性の機序
  • はじめに
  • 1. β受容体と細胞内シグナル伝達
  • 2. β遮断薬と細胞内Ca2+ハンドリング
  • 3. β遮断薬によるRyR2からのCa2+放出能の改善
  • 1) 心不全時のRyR2機能異常
  • 2) β遮断薬の不全心筋RyR2に及ぼす効果
  • おわりに
  • 4. 高齢者の慢性心不全とβ遮断薬
  • はじめに
  • 1. 高齢者の慢性心不全の疫学
  • 2. 高齢心不全患者の臨床的特徴
  • 3. 高齢心不全患者におけるβ遮断薬治療のエビデンス
  • 4. β遮断薬治療の実際と注意点
  • おわりに
  • 5. 心不全におけるβ遮断薬の使用法
  • はじめに
  • 1. β遮断薬をいつはじめるか
  • 2. 無症候性心機能低下例に使うべきか
  • 3. どのβ遮断薬を選択するか
  • 4. どこまで増量すべきか
  • 5. β遮断薬は第二選択薬か
  • 6. 拡張機能障害
  • 7. 高齢者心不全例
  • 8. レスポンダーの予測
  • 9. 炎症に及ぼす影響
  • 10. 睡眠時無呼吸症候群との関連
  • おわりに
  • 6. 不整脈を伴う慢性心不全とβ遮断薬
  • はじめに
  • 1. 慢性心不全患者におけるSCDの頻度
  • 2. 慢性心不全患者におけるSCD予測
  • 3. 慢性心不全患者のSCD予防
  • 4. 慢性心不全患者のSCDに対するβ遮断薬の効果
  • おわりに
  • 7. 拡張不全による慢性心不全とβ遮断薬
  • はじめに
  • 1. 拡張不全の発症過程
  • 2. 拡張機能障害にβ遮断薬は有効か?
  • 3. β遮断薬の拡張不全への有用性
  • 4. β遮断薬の拡張機能障害への有用性は心拍数低下によるのか?
  • おわりに
  • 8. 慢性心不全におけるβ遮断薬の効果予測
  • はじめに
  • 1. 日常診療からわかること
  • 2. 心筋線維化を利用した効果予測
  • 1) 心筋生検
  • 2) 体表面加算平均心電図
  • 3) 遅延造影MRI
  • 3. その他の効果予測因子
  • 1) ドブタミン負荷試験
  • 2) 神経体液性因子
  • 3) 123I-MIBG
  • おわりに
  • 9. 心臓リハビリテーションとβ遮断薬
  • はじめに
  • 1. 心疾患患者の運動耐容能に及ぼすβ遮断薬の影響
  • 1) 健常者,心房細動患者
  • 2) 心不全患者
  • 2. 心臓リハビリテーション / 運動療法による運動耐容能改善効果に及ぼすβ遮断薬の影響
  • 1) 健常者
  • 2) 心筋梗塞患者
  • 3) 慢性心不全患者
  • 3. β遮断薬服用患者に対する心臓リハビリテーション実施上の注意点
  • 1) 運動処方
  • 2) 運動療法導入時の心不全の一時的悪化
  • 4. おわりに
  • Part 12 非薬物療法とβ遮断薬
  • 1. 手術(心血管系手術を含む) とβ遮断薬
  • はじめに
  • 1. 術前・術中のβ遮断薬の使い方
  • 2. 術後及び集中治療室でのβ遮断薬の使い方
  • 3. 低心機能症例に対する手術とβ遮断薬
  • 4. 血管手術とβ遮断薬
  • おわりに
  • 2. CRTとβ遮断薬
  • はじめに
  • 1. β遮断薬不忍容症例におけるCRT
  • 2. β遮断薬投与とCRT手術時期
  • 3. 両心室ペーシング確保のためのβ遮断薬
  • 4. 不整脈に対するβ遮断薬
  • おわりに
  • 3. ICDとβ遮断薬
  • はじめに
  • 1. β遮断薬の予後改善効果
  • 2. ICDによる突然死の予防
  • 3. ICD時代におけるβ遮断薬の役割
  • おわりに
  • Part 13 β遮断薬使用上の注意点
  • 1. β遮断薬の副作用と禁忌
  • はじめに
  • 1. β遮断薬に対する禁忌・重篤な副作用
  • 1) 徐脈
  • 2) 末梢循環障害
  • 3) 呼吸器疾患
  • 4) 心不全
  • 5) 妊婦
  • 2. 慎重に投与すべき状態
  • 1) 糖・脂質代謝異常
  • 2) 離脱症状
  • 3) 肝・腎機能低下例
  • 4) 高齢者
  • 5) 褐色細胞腫
  • 6) 甲状腺機能亢進症
  • 3. その他の副作用
  • 1) 電解質異常(K上昇)
  • 2) 中枢神経系に対する副作用
  • 3) 性機能低下
  • 4) CPK上昇
  • おわりに
  • 2. β遮断薬の薬物相互作用
  • はじめに
  • 1. β遮断薬の薬物動態学的相互作用
  • 1) CYP2D6代謝の抑制によるもの
  • 2) P糖蛋白の排出低下によるもの
  • 2. β遮断薬の薬力学的相互作用
  • 1) 降圧薬との併用
  • 2) 抗不整脈薬との併用
  • 3) 血糖降下薬との併用
  • 4) 非ステロイド抗炎症薬との併用
  • 5) カテコールアミン系薬との併用
  • 6) PDE-5阻害薬との併用
  • おわりに
  • 臨床試験一覧・索引
  • 臨床試験一覧
  • 索引
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 β遮断薬のプロファイル

P.34 掲載の参考文献
1) Cruickshank JM, Prichard BNC:Historical. In:β-blockers in Clinical Practice, Churchill Livingstone, Edinburgh, 1988, p.1-p.8
3) Powell CE, Slater IH:Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther 122:480-488, 1958
4) Black JW, Stephenson JS:Pharmacology of new β-receptor-blocking compound (Nethalide). Lancet ii:311-314, 1962
5) Greenberg G, Brennan PJ, Miall WE:Effects of diuretic and β-blocker therapy in the Medical Research Council Trial. Am J Med 76 (2A):S45-S51, 1984
6) Aellig WH:Pindolol-A β-adrenoceptor blocking drugs with partial agonist activity:clinical pharmacological considerations. Br J Clin Pharmacol 13 (Suppl 2):S187-S189, 1982
7) Lands AM, Arnold A, McAuliff JP et al:Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597-598, 1967
9) Mancia G, De Baker G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007
10) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
11) Clifton JE, Collins I, Hallett P et al:Arylethanolamines derived from salicylamide with α-and β-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides. J Med Chem 25:670-679, 1982
12) Palazzuoli A, Calabria P, Versuri MS et al:Carvedilol:something else than a simple β-blocker? Eur Rev Med Pharmacol Sci 6:115-126, 2002
15) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
16) Australia-New Zealand Heart Failure Research Collaborative Group:Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92:212-218, 1995
18) Flannery G, Gehrig-Mills R, Billah B et al:Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving β-blockers. Am J Cardiol 101:865-869, 2008
20) 築山久一郎, 小林俊一, 峰岸慎太郎:高血圧から慢性心不全までの大規模介入試験からみたβ遮断薬の評価. Ther Res 29:9-32, 2008
P.39 掲載の参考文献
1) Prichard BNC:The second Lilly Prize Lecture, University of Newcastle, July 1977. β-adrenergic receptor blockade in hypertension, past, present, and future. Br J Clin Pharmacol 5:379-399, 1978
2) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
3) CIBIS-II investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBISII):a randomised trial. Lancet 353:9-13, 1999
5) Packer M, Coats AJS, Fowler MB et al;Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
6) The CAPRICORN investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomized trial. Lancet 357:1385-1390, 2001
8) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
P.45 掲載の参考文献
1) Hoffmann C, Leitz MR, Oberdorf-Maass S et al:Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 369:151-159, 2004
2) Baker JG:The selectivity ofβ-adrenoreceptor antagonists at the human β1, β2 andβ3 adrenoceptors. Br J Pharmacol 144:317-322, 2005
3) Molenaar P, Chen L, Semmler AB et al:Human heart β-adrenoceptors:β1-adrenoceptor diversification through`affinity states' and polymorphism. Clin Exp Pharmacol Physiol 34:1020-1028, 2007
4) Lohse MJ, Engelhardt S, Eschenhagen T:What is the role of β-adrenergic signaling in heart failure? Circ Res 93:896-906, 2003
5) Noma T, Lemaire A, Naga Prasad SV et al:β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458, 2007
6) Kim IM, Tilley DG, Chen J et al:β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 105:14555-14560, 2008
7) 坂本篤裕:ランジオロール (オノアクト(R)50注) . 臨麻 26:2002

Part 2 β遮断薬に関する最近の話題

P.53 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009
3) Bangalore S, Sawhney S, Messerli FH:Relation of β-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52:1482-1489, 2008
4) Bangalore S, Wild D, Parkar S et al:β-Blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 52:1062-1072, 2008
5) 日本循環器学会:心筋梗塞二次予防に関するガイドライン (2006年改訂版) . 循環器病の診断と治療に関するガイドライン (2004-2005年度合同研究班報告) <http://www.j-circ.or.jp/guideline/pdf/JCS2006_ishikawa_h.pdf>
6) 日本循環器学会:急性心筋梗塞 (ST上昇型) の診療に関するガイドライン:循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告). Jpn Circ J 72 (Suppl IV):S1347-S1442, 2008
7) 日本循環器学会:冠攣縮性狭心症の診断と治療に関するガイドライン:循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告). Jpn Circ J 72 (Suppl IV), S1195-S1238, 2008
8) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
10) 日本循環器学会:慢性心不全治療ガイドライン:循環器病の診断と治療に関するガイドライン (2004年度合同研究班報告) <http://www.j-circ.or.jp/guideline/pdf/JCS2005_matsuzaki_h.pdf>
12) 日本循環器学会:不整脈薬物治療に関するガイドライン:循環器病の診断と治療に関するガイドライン (2002-2003年度合同研究班報告). Circ J 68 (Supple IV):981-1053, 2004
P.60 掲載の参考文献
4) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
12) β-Blocker Evaluation of Survival Trial Investigators:A trial of theβ-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667, 2001
14) Hillege HL, Nitsch D, Pfeffer MA et al; Candesartan in Heart Failure:Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators:Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671-678, 2006
15) Cice G, Ferrara L, D' Andrea A et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:a prospective, placebo controlled trial. J Am Coll Cardiol 41:1438-1444, 2003
16) Abbott KC, Trespalacios FC, Agodoa LY et al:β-Blocker use in long-term dialysis patients:association with hospitalized heart failure and mortality. Arch Intern Med 164:2465-2471, 2004
17) Wright RS, Reeder GS, Herzog CA et al:Acute myocardial infarction and renal dysfunction:a high-risk combination. Ann Intern Med 137:563-570, 2002
18) Bakris GL, Hart P, Ritz E:β Blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006
P.66 掲載の参考文献
1) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
2) Waagstein F, Bristow MR, Swedberg K et al; Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:Beneficial effects of metoprolol inidiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993
3) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
4) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
5) Packer M, Bristow MR, Cohn JN et al; U. S. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
6) Packer M, Coats AJS, Fowler MB et al; Carvedilol Prospective Randomized Cumulative Survival Study Group:Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
7) The Cardiac Insufficiency Bisoprolol Study H (CIBIS-II):a randomised trial. Lancet 353:9-13, 1999
8) The Xamoterol in Severe Heart Failure Study Group:Xamoterol in severe heart failure. Lancet 336:1-6, 1990
9) The Beta-Blocker Evaluation of Survival Trial Investigators:A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. Engl J Med 344:1659-1667, 2001
10) Flather MD, Shibata MC, Coats AJS et al;SENIORS Investigators:Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215-225, 2005
12) Metra M, Giubbini R, Nodari S et al:Differential effects of β-blockers in patients with heart failure:A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102:546-551, 2000
15) Kaye DM, Lambert GW, Lefkovits J et al:Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23:570-578, 1994
16) Cohn J, Levine T, Oliveri M et al:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823, 1984
17) Azevedo ER, Kubo T, Mak S et al:Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure:differential effects on sympathetic activity. Circulation 104:2194-2199, 2001
19) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blockers:Importance of ancillary properties. Prog Cardiovasc Dis 39:445-456, 1997
20) Freemantle N, Cleland J, Young P et al:β Blockade after myocardial infarction:systematic review and meta regression analysis. BMJ 318:1730-1737, 1999
21) Freemantle N, Urdahl H, Eastaugh J et al:What is the place ofβ-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis) interpretation. . Prog Cardiovasc Dis 44:243-250, 2002
22) Kjekshus J:Comments-Beta-blockers:Heart rate reduction:a mechanism of benefit. Eur Heart J 6:189, 1985
24) Jonsson G, Abdelnoor M, Mifller C et al:A comparisonof the two β-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. A single-centre, randomized study of 232 patients. Cardiology 103:148-155, 2005
26) Haas SJ, Vos T, Gilbert RE et al:Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146:848-853, 2003
28) Dahlof B, Devereux RB, Kjeldsen SE et al:LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol Lancet 359:995-1003, 2002
32) Bakris GL, Hart P, Rits E:Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006
33) Cice G, Ferrara L, D:Andrea A et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438-1444, 2003
34) Tomlinson B, Bompart F, Graham BR et al:Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Drugs 36 (Suppl 6):S37-S47, 1988
35) Marchi F, Ciriello G:Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria:a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 12:212-221, 1995
37) 築山久一郎, 小林俊一, 峯岸慎太郎:高血圧から慢性心不全までの大規模介入試験からみたβ遮断薬の評価Ther Res 29:9-32, 2008
P.72 掲載の参考文献
1) 厚生労働省:平成18年度国民医療費の概況 <http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/06/index.html>
2) Turnbull F, Neal B, Algert C et al; Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003
3) 循環器病予防研究会:第5次循環器疾患基礎調査結果, 中央法規出版, 東京, 2003
4) 厚生労働省健康局総務課生活習慣病対策室:平成18年国民健康・栄養調査結果の概要, 厚生労働省, 東京, 2008, p. 31
5) 厚生労働省:平成18年人口動態統計の概況 <http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakuteiO6/index.html>
6) Chobanian AV, Bakris GL, Black HR et al:National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The JNC 7 Report. JAMA 289:2560-2572, 2003
8) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009
10) Poole-Wilson PA, Swedberg K, Cleland JGF et al:Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet 362:7-13, 2003
14) Bacquet P, Levy E, McGuire A et al;CIBIS-II Investigators and Health Economics Group:Reduced costs with bisoprolol treatment for heart failure:an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-H). Eur Heart J 22:1021-1031, 2001
17) Inomata T, Izumi T, Kobayashi M:Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. Cirl J 68:35-40, 2004
P.79 掲載の参考文献
1) The fourth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC IV). Arch Intern Med 148:1023-1038, 1988
2) The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153:154-183, 1993
3) The sixth report of the Joint National Committee on detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157:2413-2446, 1997
4) National Institute for Health and Clinical Excellence Hypertension:management of hypertension in adults in primary care (NICE clinical guideline update <http://www.nice.org.uk8/CGO3>)
5) 日高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009. 日本高血圧学会, 東京, 2009
7) World Health Organization:Prevention of cardiovascular disease:guidelines for assessment and management of total cardiovascular risk, WHO, Geneva, 2007
8) Khan NA, McAlister FA, Rabkin SW et al;Canadian Hypertension Education Program:The 2006 Canadian Hypertension Education Program recommendation for the management of hypertension:Part II-Therapy. Can J Cardiol 22:583-593, 2006
9) Mancia G, DeBacker G, Dominiczak A et al; Management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007
12) Lindholm LH, Carlberg B, Samuelsson O:Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005
13) Messerli FH, Grossman E, Goldbourt U:Are β-blockers efficacious as first-line theraphy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998
15) Weber MA, Bakris GL, Giles T et al:β-Blockers in the treatment of hypertension:new data, new directions. J Clin Hypertens (Greenwich) 10:234-238, 2008
16) Arterial hypertension. Report of a WHO expert committee. World Health Organ Tech Rep Ser 628:7-56, 1978
17) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
P.83 掲載の参考文献
2) Komajda M, Follath F, Swedberg K et al;Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology:The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2:treatment. Eur Heart J 24:464-474, 2003
4) Shelton RJ, Rigby AS, Cleland JG et al:Effect of a community heart failure clinic on uptake of β blockers by patients with obstructive airways disease and heart failure. Heart 92:331-336, 2006
7) 日本循環器学会:循環器病の診断と治療に関するガイドライン (2004年度合同研究班報告):慢性心不全治療ガイドライン (2005年改訂版) (ホームページ公開のみ) <http://plaza.uminacjp/~circ/guideline/JCS2005_matsuzaki_h.pdf>
8) Hunt SA, Abraham WT, Chin MH et al;American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society:ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation:endorsed by the Heart Rhythm Society. Circulation 112:e154-e235, 2005
9) Dickstein K, Cohen-Solal A, Filippatos G et al:Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology:ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388-2442, 2008

Part 3 β遮断薬の各臓器への作用を探る

P.92 掲載の参考文献
6) Noma T, Lemaire A, Naga Prasad SV et al:β-Arrestinmediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458, 2007
7) Zhu WZ, Wang SQ, Chakir K et al:Linkage ofβ1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest 111:617-625, 2003
8) Patterson AJ, Zhu W, Chow A et al:Protecting the myocardium:a role for the β2 adrenergic receptor in the heart. Crit Care Med 32:1041-1048, 2004
9) Zhu WZ, Zheng M, Koch WJ et al:Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA, 98:1607-16122001
11) Feldman AM, Cates AE, Veazey WB et al:Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82:189-197, 1988
12) Neumann J, Schmitz W, Scholz H et al:Increase in myocardial Gi-proteins in heart failure. Lancet ii:936-937, 1988
13) Marx SO, Reiken S, Hisamatsu Y et al:PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor):defective regulation in failing hearts. Cell 101:365-376, 2000
14) El-Armouche A, Pamminger T, Ditz D et al:Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 61:87-93, 2004
15) Ungerer M, Bohm M, Elce JS et al:Altered expression ofβ-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87:454-463, 1993
16) Engelhardt S, Hein L, Wiesmann F et al:Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064, 1999
17) Bisognano JD, Weinberger HD, Bohlmeyer TJ et al:Myocardial-directed overexpression of the human β1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32:817-830, 2000
19) Iwase M, Uechi M, Vatner DE et al:Cardiomyopathy induced by cardiac GS α overexpression. Am J Physiol Heart Circ Physiol 272:H585-H589, 1997
20) Antos CL, Frey N, Marx SO et al:Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89:997-1004, 2001
21) Dorn GW H, Tepe NM, Lorenz JN et al:Low-and high-level transgenic expression ofβ2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc Natl Acad Sci USA 96:6400-6405, 1999
22) Bernstein D, Fajardo G, Zhao M et al:Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 289:H2441-H2449, 2005
23) Koch WJ, Rockman HA, Samama P et al:Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a beta ARK inhibitor. Science 268:1350-1353, 1995
24) Rockman HA, Choi DJ, Rahman NU et al:Receptorspecific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA 93:9954-9959, 1996
25) Rockman HA, Chien KR, Choi DJ et al:Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in genetargeted mice. Proc Natl Acad Sci USA 95:7000-7005, 1998
26) Liggett SB, Cresci S, Kelly RJ et al:AGRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med 14:510-517, 2008
27) Mialet Perez J, Rathz DA, Petrashevskaya NN et al:β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300-1305, 2003
28) Small KM, Wagoner LE, Levin AM et al:Synergistic polymorphisms of β1-and α2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135-1142, 2002
29) Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al:A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288-11293, 2006
30) Liggett SB, Wagoner LE, Craft LL et al:The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102:1534-1539, 1998
31) Yasumura Y, Takemura K, Sakamoto A et al:Changes in myocardial gene expression associated with β-blocker therapy in patients with chronic heart failure. J Card Fail 9:469-474, 2003
32) Shigeyama J, Yasumura Y, Sakamoto A et al:Increased gene expression of collagen Types I and III is inhibited by β-receptor blockade in patients with dilated cardiomyopathy. Eur Heart J 26:2698-2705, 2005
34) Opie LH:Mechanisms of cardiac contraction and relaxation. In:Braunwald's Heart Disease 8th Edition, eds by Libby P, Bonow RO, Mann DL et al, W B Sounders, Philadelphia, PA, 2007, p.509-p.539
35) Eschenhagen T:β-adrenergic signaling in heart failure-adapt or die. Nat Med 14:485-487, 2008
36) 長谷川洋, 小室一成:β遮断薬の心筋に対する作用. β遮断薬のすべて第2版, 荻原俊男, 築山久一郎, 横山光宏編, 先端医学社, 東京, 2004, p.58-p.64
P.99 掲載の参考文献
1) Guimaraes S, Moura D:Vascular adrenoceptors:an update. Pharmacol Rev 53:319-356, 2001
2) Kaumann AJ:Four β-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci 18:70-76, 1997
3) Molenaar P, Sarsero D, Kaumann AJ:Proposal for the interaction of non-conventional partial agonists and catecholamines with the 'putative β4-adrencceptor' in mammalian heart. Clin Exp Pharmacol Physiol 24:647-656, 1997
4) Galitzky J, Langin D, Montastruc J-L et al:On the presence of a putative fourth β-adrenoceptor in human adipose tissue. Trends Pharmacol Sci 19:164-166, 1998
5) Granneman JG:The putative β4-adrenergic receptor is a novel state of the βradrenergic receptor. Am J Physiol Endocrinol Metab 280:E199-E202, 2001
6) Queen LR, Ferro A:β-adrenergic receptors and nitric oxide generation in the cardiovascular system Cell Mol Life Sci 63:1070-1083, 2006
7) Ritter JM:Nebivolol:endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 38 (supple 3):S13-S16, 2001
8) Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al:Third-generation β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux. Circulation 107:2747-2752, 2003
9) Intengan HD, Schiffrin EL:Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J Cardiovasc Pharmacol 35:763-768, 2000
10) Broeders MA, Doevendans PA, Bekkers BC et al:Nebivolol:a third generation β-blocker that augments vascular nitric oxide release:endothelial β2-adrenergic receptor-mediated nitric oxide production. Circulation 102:677-684, 2000
11) Dessy C, Saliez J, Ghisdal P et al:Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation 112:1198-1205, 2005
12) Dandona P, Karne R, Ghanim H et al:Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101:122-124, 2000
13) Feuerstein G, Yue TL, Ma X et al:Novel mechanisms in the treatment of heart failure:inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 41 (Suppl 1):17-24, 1988
15) Maggi E, Marchesi E, Covini D et al:Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 27:532-538, 1996
17) Ohlstein EH, Vickery L, Arleth A et al:Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 16:163-177, 1994
18) Ohlstein EH, Douglas SA, Sung CP et al:Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 90:6189-6193, 1993
19) Whittington-Coleman PJ, Carrier O Jr, Douglas BH:The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 18:337-345, 1973
21) Linden T, Camejo G, Wiklund O et al:Effect of short-term βblockade on serum lipid levels and on the interaction of LDL with human arterial Proteoglycans. J Clin Pharmacol 30 (Suppl 2):S124-S131, 1990
23) Wikstrand J, Berglund G, Hedblad B et al:Antiatherosclerotic effects of β-blockers. Am J Cardiol 91 (Suppl H):S25-S29, 2003
24) Wikstrand J, Warnold I, Tuomilehto J et al:Metprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 17:579-588, 1991
P.104 掲載の参考文献
2) 北川一夫, 松本昌泰, 堀正二:β遮断薬の脳循環に対する作用. β遮断薬のすべて, 荻原俊男, 築山久一郎, 横山光宏編, 先端医学社, 東京, 2000, p.75-p.79
3) 北川一夫, 堀正二:β遮断薬の脳循環に対する作用. β遮断薬のすべて第2版, 荻原俊男, 築山久一郎, 横山光宏編, 先端医学社, 東京, 2004, p.75-p.80
4) Powers WJ, Zazulia AR, Videen TO et al:Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology 57:18-24, 2001
9) Goyagi T, Kimura T, Nishikawa T et al:β-adrenoreceptor antagonists attenuate brain injury after transient focal ischemia in rats. Anesth Analg 103:658-663, 2006
10) Strosznajder RP, Jesko H, Dziewulska J:Effect of carvedilol on neuronal survival and poly (ADPribose) polymerase activity in hippocampus after transient forebrain ischemia. Acta Neurobiol Exp (Wars) 65:137-144, 2005
12) Dziedzic T, Slowik A, Pera J et al:β-blockers reduce the risk of early death in ischemic stroke. J Neurol Sci 252:53-56, 2007
14) Prass K, Braun JS, Dirnagl U et al:Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke 37:2607-2612, 2006
P.111 掲載の参考文献
1) Campese VM, Krol E:Neurogenic factors in renal hypertension. Curr Hypertens Rep 4:256-260, 2002
2) Campese VM, Kogosov E:Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878-882, 1995
3) Salplachta J, Bartosikova L, Necas J:Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy. Gen Physiol Biophys 21:189-195, 2002
5) Cice G, Ferrara L, D:Andrea AE et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:a prospective palcebo-controlled trial. J Am Coll Cardiol 41:1438-1444, 2003
6) Klein IH, Ligtenberg G, Oey PL et al:Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:2427-2433, 2001
7) Zoccali C, Mallamaci F, Parlongo S et al:Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359, 2002
9) Hausberg M, Kosch M, Harmelink P et al:Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974-1979, 2002
10) Antman EM, Anbe DT, Armstrong PW et al:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110:588-636, 2004
11) Eknoyan G:On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure:a first step to improve the outcomes. Am J Kidney Dis 32 (Suppl 3):S1-S4, 1998
14) Bakris GL:Role for β-blockers in the management of diabetic kidney disease. Am J Hypertens 16:S7-S12, 2003
15) Abbot KC, Trespalacios FC, Agodoa LY et al:β-Blocker use in long-term dialysis patients:association with hospitalized heart failure and mortality. Arch Intern Med 164:2465-2471, 2004
16) Tresparacios FC, Taylor AJ, Agodoa LY et al:Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 62:1799-1805, 2002
18) Ong HT:β blockers in hypertension and cardiovascular disease. BMJ 334:946-949, 2007
22) Bauer JH, Reams GP:Antihypertensive drugs. In:Brenner & Rector's the Kidney 5th ed, eds by Brenner BM, Rector FC, W B Saunders, Philadelphia, 1996, p.2331-p.2381
25) Haeusler G, Schliep HJ, Schelling P et al:High β1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol 8 (Suppl 11):S2-S15, 1986
27) Ito S, Nagasawa T, Abe M et al:Strain vessel hypothesis. A viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res, in press
28) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
30) Messerli FH, Bell DS, Fonseca V et al; GEMINI Investigators:Body weight changes with β-blocker use:results from GEMINI. Am J Med 120:610-615, 2007
32) Holdaas H, Hartmann A, Berg KJ et al:Contrasting effects of angiotensin converting inhibitor and α1 antagonist on albuminuria in insulin-dependent diabetes mellitus patients with nephropathy. J Intern Med 237:63-71, 1995
33) Rachmani R, Levi Z, Slavachevsky I et al:Effect of an α-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria:a randomized cross-over study. Nephron 80:175-182, 1998
35) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-blocking agents? Am J Hypertens 11:1258-1265, 1998
36) Javanovic D, Jovovic D, Mihailovic-Stanojevic N et al:Influence of carvedilol on chronic renal failure progession in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 63:446-453, 2005
37) Uehara Y, Takada S, Hirawa N et al:Vasoconstrictors and renal protection induced by β1-selective adrenoceptor antagonist bisoprolol. J Cardiovasc Pharmacol 23:897-906, 1994
38) Bakris GL, Hart P, Ritz E:β blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006

Part 4 β遮断薬の糖・脂質代謝への影響をみる

P.119 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009
2) Sawicki PT, Siebenhofer A:Betablocker treatment in diabetes mellitus. J Intern Med 250:11-17, 2001
3) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
4) Jonas M, Reicher-Reiss H, Boyko V et al;Bezafibrate Infarction Prevention (BIP) Study Group:Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 77:1273-1277, 1996
5) Lithell H, Pollare T, Berne C et al:The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. Blood Press 1:20-26, 1992
7) Pollare T, Lithell H, Morlin C et al:Metabolic effects of diltiazem and atenolol:results from a randomized, double-blind study with parallel groups. J Hypertens 7:551-559, 1989
8) Pollare T, Lithell H, Selinus I et al:Sensitivity to insulin during treatment with atenolol and metoprolol:a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298:1152-1157, 1989
11) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity:the carvedilol-metoprolol study. J Hypertens 14:489-494, 1996
12) Hansson L, Lindholm LH, Niskanen L et al:Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
13) Dahlof B, Devereux RB, Kjeldsen SE et al;LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
14) Pepine CJ, Handberg EM, Cooper-DeHoff RM et al:A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST):a randomized controlled trial. JAMA 290:2805-2816, 2003
15) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
16) Malminiemi K:Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 9:295-304, 1995
17) Giugliano D, Acampora R, Marfella R et al:Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126:955-959, 1997
20) Eggertsen R, Sivertsson R, Andren L et al:Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 1O (Suppl 11):S97-S100, 1987
P.126 掲載の参考文献
1) Working Group on Management of Patients with Hypertension and High Blood Cholesterol:National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 114:224-237, 1991
2) Frishman WH, Clark A, Johnson B:The effects of cardiovascular drugs on plasma lipids and lipoproteins. In:Cardiovascular Pharmacotherapeutics, eds by Frishman WH, Sonnenblick EH, Sica DA, McGraw-Hill, Columbus, 1997, p.1515-p1559
3) Mantel-Teeuwisse AK, Kloosterman JME, Maitland-van der Zee AH et al:Drug-induced lipid changes:a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 24:443-456, 2001
5) Kasiske BL, Ma JZ, Kalil RSN et al:Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122:133-141, 1995
6) Fogari R, Zoppi A, Corradi L et al:β-Blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 33:534-539, 1999
10) Hauf-Zachariou U, Widmann L, Zulsdorf B et al:A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 45:95-100, 1993
11) Malminiemi K:Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 9:295-304, 1995
13) 武田和夫, 篠山重威, 中川雅夫ほか:本態性高血圧症に対する血管拡張性β1遮断薬塩酸セリプロロール (セレクトール(18)錠) の長期投与における有用性と血清脂質に及ぼす影響の検討. 臨医薬 12:3161-3180, 1996
14) 戸塚光哉, 宮下洋, 伊藤嘉晃ほか:Celiprolol hydrochloride の脂質代謝に及ぼす影響 (特に low density lipoproteinのサイズ変化について) . 日老医誌 38:352-359, 2001
16) Kubo M, Hostetler KY:Inhibition of purified bovine milk lipoprotein lipase by propranolol and other beta-adrenergic blockers in vitro. Biochem Biophys Acta 918:168-174, 1987
17) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-blocking agents? Am J Hypertens 11:1258-1265, 1998
18) Sharma AM, Pischon T, Hardt S et al:Hypothesis:β-tigators:Body weight changes with β-blocker use:results from GEMINI. Am J Med 120:610-615, 2007
19) Messerli FH, Bell DSH, Fonseca V et al;GEMINI Investigators: Body weight changes with β-blocker use: results from GEMINI. Am J Med 120: 610-615, 2007
20) Malminiemi K; Celiprolol Multicenter Study group:Long-term celiprolol therapy lowers fasting plasma leptin levels. Cardiovasc Drugs Ther 14:67-75, 2000
23) Ueshiba H, Yoshino G:Effects of celiprolol on insulin resistance and steroid hormones in essential hypertension. Ther Res 29:569-575, 2008
P.132 掲載の参考文献
3) Higashiura K, Ura N, Takada T et al:Alteration of muscles fiber composition linking to insulin resistance and hypertension in fructose-fed rats. Am J Hypertens 12:596-602, 1999 132
4) Togashi N, Ura N Higashiura K et al:The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18:1605-1610, 2000
5) Togashi N, Ura N, Higashiura K et al:Effects of TNF-α-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 39:578-580, 2002
6) Furuhashi M, Ura N, Higashiura K et al:Blockade of rennin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 42:76-81, 2003
7) Ogihara T, Nakao K, Fukui T et al; CASE-J Study Group:Clinical outcomes in hypertensive patients with high cardiovascular risks:principal results of candesartan antihypertensive survival evaluation in Japan (CASE-J) study. J Hypertens 24 (Suppl 6):30, 2006
8) Iimura O, Shimamoto K, Matsuda K et al:Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensive. Am J Hypertens 8:353-357, 1994
9) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-bloking agents? Am J Hypertens 11:1258-1265, 1998
10) Bakris GL, Hart P, Ritz E:β blockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006
11) Bakris GL, Fonseca V, Katholi RE et al;GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol inpatients with type2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA 292:2227-2236, 2004

Part 5 β遮断薬の酸化ストレスへの効果を探る

P.137 掲載の参考文献
1) 廣岡良隆:"脳"と高血圧. 分子心血管病2:167-175, 2001
2) Dampaney RAL Polson JW, Potts PD et al:Functional organization of brain pathways subserving the baroreceptor reflex:studies in conscious animals using immediate early gene expression. Cell Mol Neurobiol 23:597-616, 2003
3) Peterson JR, Sharma RV, Davisson RL:Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep 8:232-241, 2006
4) 0liveira-Sales EB, Dugaich AP, Carillo BA et al:Oxidative stress contributes to renovascular hypertension. Am J Hypertens 21:98-104, 2008
7) Zimmerman MC, Lazartigues E, Lang JA et al:Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91:1038-1045, 2002
8) Dai X, Cao X, Kreulen DL et al:Superoxide anion is elevated in sympathetic neurons in DOCA-salt hypertension via activation of NADPH oxidase. Am J Physiol Heart Circ 290:H1019-H1026, 2006
9) Remondino A, Kwon SH, Communal C et al:β-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92:136-138, 2003
11) Cargnoni A, Ceconi C, Bernocchi P et al:Reduction of oxidative stress by carvedilol:role in maintenance of ischemic myocardium viability. Cardiovasc Res 47:556-566, 2000
12) Kawai K, Qin F, Shite J et al:Importance of antioxidant and antiapoptotic effects of β-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 287:H1003-H1012, 2004
14) Flesch M, Maack C, Cremers B et al:Effects of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1OO:346-353, 1999
15) Gourine A, Bondar SI, Spyer KM et al:Beneficial effects of the central nervous system β-adrenoceptor blockade on the failing heart. Circ Res 102:633-636, 2008
P.144 掲載の参考文献
1) 金森崇, 太田成男:電子伝達とエネルギー転換系. 新ミトコンドリア学, 内海耕憧, 井上正康編, 共立出版, 東京, 2001, p.8-p.13
4) Xiao L, Pimentel DR, Wang J et al:Role of reactive oxygen species and NAD(P)H oxidase in α1-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282:C926-C934, 2002
8) Remondino A, Kwon SH, Communal C et al:β-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92:136-138, 2003
10) Kim SM, Chen L, Faulhaber-Walter R et al:Regulation of renin secretion and expression in mice deficient in β1 and β2-adrenergic receptors. Hypertension 50:103-109, 2007
12) Briest W, H61zl A, Rassler B et al:Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 52:265-273, 2001
16) Communal C, Singh K, Pimentel DR et al:Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 98:1329-1334, 1998
19) Kukin ML, Kalman J, Charney RH et al:Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651, 1999
20) Flesch M, Maack C, Cremers B et al:Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100:346-353, 1999
P.150 掲載の参考文献
6) Nakamura K, Fushimi K, Kouchi H et al:Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin H. Circulation 98:794-799, 1998
7) Kakishita M, Nakamura K, Asanuma M et al:Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type la receptor. J Cardiovasc Pharmacol 42 (Suppl 1):S67-S70, 2003
10) Treasure CB, Vita JA, Cox DA et al:Endotheliumdependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81:772-779, 1990
13) Ide T, Tsutsui H, Hayashidani S et al:Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 88:529-535, 2001
16) Dieterich S, Bieligk U, Beulich K et al:Gene expression of antioxidative enzymes in the human heart:increased expression of catalase in the endstage failing heart. Circulation 101:33-39, 2000
17) Kukin ML, Kalman J, Charney RH et al:Prospective, randomized comparison of effect of long-term 3. 心不全における酸化ストレスとβ遮断薬 treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651, 1999
18) Chin BS, Langford NJ, Nuttall SL et al:Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. Eur J Heart Fail 5:171-174, 2003
21) Barki-Harrington L, Luttrell LM, Rockman HA:Dual inhibition ofβ-adrenergic and angiotensin n receptors by a single antagonist:afunctional role for receptor-receptor interaction in vivo. Circulation 108:1611-1618, 2003
22) Ohtsuka T, Hamada M, Hiasa G et al:Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37:412-417, 2001
24) Dandona P, Karne R, Ghanim H et al:Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101:122-124, 2000
26) Mollnau H, Schulz E, Daiber A et al:Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. ・Arterioscler Thromb Vasc Biol 23:615-621, 2003
27) Oelze M, Daiber A, Brandes RP et al:Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin H-treated rats. Hypertension 48:677-684, 2006
28) Yue TL, Cheng HY, Lysko PG et al:Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263:92-98, 1992
29) Flesch M, Maack C, Cremers B et al:Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1OO:346-353, 1999

Part 6 高血圧治療におけるβ遮断薬の有用性を探る

P.156 掲載の参考文献
1) Kaplan NM:β-Adrenergic receptor blockers. In:Clinical Hypertension 7th ed, Williams & Wilkins, Baltimore, 1998, p. 205-p213
2) Cruickshank JM:Are we misunderstanding β-blockers. Int J Cardio 120:10-27, 2007
3) Niarchos AP, Laragh JH:Renin dependency of blood pressure in isolated systolic hypertension. Am J Med 77:407-414, 1984
4) Koepke JP, Jones S, DiBona GF:Hypothalamicβ2-adrenoceptor control of renal sympathetic nerve activity and urinary sodium excretion in conscious, spontaneously hypertensive rats. Circ Res 58:241-248, 1986
6) Schindler C, Dobrev D, Grossmann M et al:Mechanisms ofβ-adrenergic receptor-mediated venodilation in humans. Clin Pharmacol Ther 75:49-59, 2004
7) Prichard BN, Owens CW:Mode of action of β-adrenergic blocking drugs in hypertension. Clin Physiol. Biochem 8 (Suppl 2):S1-S1O, 1990
9) Dahlof B, Sever PS, Poulter NR et al;ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. 」Lancet 366:895-906, 2005
10) Dahlof B, Devereux RB, Kjeldsen SE et al;LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
P.160 掲載の参考文献
4) Lindholm LH, Carlberg B, Samuelsson O:Should βblockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005
8) Barzilay JI, Davis BR, Cutler JA et al;ALLHAT Collaborative Research Group:Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment:areport from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . Arch Intern Med 166:2191-2201, 2006
12) Bakris GL, Fonseca V, Katholi RE et al;GEMINI Investigators:Differential effects ofβ-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
13) Messerli FH, Bell DS, Fonseca V et al;GEMINI Investigators:Body weight changes withβ-blockers use:Results from GEMINI. Am J Med 120:610-615, 2007
14) Bell DS, Bakris GL, McGill JB:Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab 2008, in press
P.166 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009年版 (JSH2009), 日本高血圧学会, 東京, 2009
4) 築山久一郎, 小林俊一, 峯岸慎太郎:State of the Art高血圧臨床研究の動向2008高血圧から慢性心不全までの大規模介入試験からみたβ遮断薬の評価. Ther Res 29:9-32, 2008
5) Morgan TO, Anderson AI, MacInnis RJ:ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14:241-247, 2001
6) Deary AJ, Schumann AL Murfet H et al:Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 20:771-777, 2002
7) Smith SC Jr, Allen J, Blair SN et al;AHA/ACC; National Heart, Lung, and Blood Institute:AHA/ACC guidelines for secondary prevention forpatients with coronary and other atherosclerotic vascular disease:2006 update:endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363-2372, 2006
8) Japaneseβ-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators:Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93:969-973, 2004
9) 勝田洋輔, 今泉勉:β遮断薬・β遮断薬. 臨と研 80:22-26, 2003
10) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
11) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
12) Packer M, Bristow MR, Cohn JN et al;US. Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
14) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial. Lancet 353 19-13, 1999
15) Packer M, Coats AJ, Fowler MB et al;Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
16) Poole-Wilson PA, Swedberg K, Cleland JG et al; Carvedilol Or Metoprolol European Trial Investigators:Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial. Lancet 362:7-13, 2003
18) Lindholm LH, Ibsen H, Dahl?f B et al;LIFE Study Group:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:1004-1010, 2002
19) Dahl?f B, Sever PS, Poulter NR et al;ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
20) McFarlane SI, Sowers JR:Treatment of diabetes and hypertension. In:Hypertension Primer:The Essentials of High Blood Pressure 3rd Ed, eds by Izzo JL, Black HR, Lippincott Williams & Wilkins, Philadelphia, 2003, p. 488-p. 491
23) Wikstrand J, Warnold I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988
24) Messerli FH, Grossman E, Goldbourt U:Are betablockers efficacious as first-line therapy for hypertension in the elderly?Asystematic review. JAMA 279:1903-1907, 1998
P.173 掲載の参考文献
2) Parving HH, Lehnert H, Brochner-Mortensen J et al; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
3) Lewis EJ, Hunsicker LG, Clarke WR et al:Collaborative Study Group:Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
4) Dahlof B, Devereux RB, Kjeldsen SE et al:LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
6) Suzuki H, Moriwaki K, Kanno Y et al:Comparison of the effects of an ACE inhibitor and αβblocker on the progression of renal failure with left ventricular hypertrophy:preliminary report. Hypertens, Res 24:153-158, 2001
7) Suzuki H, Nakamoto H, Nemoto H et al:Control of blood pressure and prevention of end-organ damage in patients with accelerated hypertension by combination with arotinolol and extended release nifedipine. Hypertens Res 23:159-166, 2000
8) Nakamoto H, Nemoto H, Sugahara S et al:Nifedipine and arotinolol in combination for acceleratedmalignant hypertension:results of one year followup. Hypertens Res 22:75-80, 1999
9) Kuwajima I, Suzuki Y, Otsuka K et al:Effects of α, β-blocker, arotinolol chloride, on 24-h blood pressure-difference between elderly and younger hypertensive patients. J Clin Pharm Ther 18:275-280, 1993
10) van Zwieten PA:An overview of the pharmacodynamic properties and therapeutic potential of combined α-andβ-adrenoceptor antagonists. Drugs 45:509-517, 1993
11) Sica DA, Black HR:Pharmacologic considerations in the positioning ofβ-blockers in antihypertensive therapy. Curr Hypertens Rep 10:330-335, 2008
12)Kveiborg B, Major-Petersen A, Christiansen B et al:Carvedilol in the treatment of chronic heart failure:lessons from the Carvedilol Or Metoprolol European Trial. Vasc. Health Risk Manag 3:31-37, 2007
13) Bakris GL, Hart P, Ritz E:βblockers in the management of chronic kidney disease. Kidney Int 70:1905-1913, 2006
15) Stroe AF, Gheorghiade M:Carvedilol:β-blockade and beyond. Rev Cardiovasc Med 5 (Suppl 1):S18-S27, 2004
16) Messerli FH, Grossman E:β-blockers in hypertension:is carvedilol different? Am J Cardiol 93 (9A):7B-12B, 2004
18) Agodoa LY, Appel L, Bakris GL et al;African American Study of Kidney Disease and Hypertension (AASK) Study Group:Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis:a randomized controlled trial. JAMA 285:2719-2728, 2001
19) Welten GM, Chonchol M, Hoeks SE et al:β-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. Kidney Int 72:1527-1534, 2007
20) Suzuki H:Association between β-blocker use and reduced mortality after vascular surgery in patients with kidney disease. Nat Clin Pract Nephrol 4:128-129, 2008
23) Norris K, Bourgoigne J, Gassman J et al:AASK Study Group:Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48:739-751, 2006
25) Bakris GL:Role forβ-blockers in the management of diabetic kidney disease. Am J Hypertens 16:7S-12S, 2003
26) 大石誠一, 佐々木雅人, 森岡由紀:αβ受容体遮断薬 (YM-09538) による褐色細胞腫の治療-ラベタロールおよびブナゾシンとの比較. 臨と研 64:2274-2250, 1987
27) 吉永馨, 荒川規矩男:褐色細胞腫21例における Labetalolの効果. ホルモンと臨 29:515-522, 1981
28) Geffner DL, Hershman JM:β-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 93:61-68, 1992
29) Reneland R, Alvarez E, Andersson PE et al:Induction of insulin resistance byβ-blockade but not ACE-inhibition:long-term treatment with atenolol or trandolapril. J Hum Hypertens 14:175-180, 2000
30) Jacob S, Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:do we have to redefine the role of β-blocking agents? AM J Hypertens II:1258-1265, 1998
31) Kosegawa I, Inaba M, Morita T et al:Effect of the vasodilatory β-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 20:751-761, 1998
32) Fogari R, Zoppi A, Lazzari P et al:Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 11:753-757, 1997
33) Schneider M, Lerch M, Papiri M et al:Metabolic neutrality of combined verapamil-trandolapril treatment in contrast toβ-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 14:669-677, 1996
34) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with twoβ-blocking agents on insulin sensitivity:the carvedilolmetoprolol study. 1. Hypertens 14:489-494, 1996
37) Fonseca V, Bakris GL, Bell DS et al;GEMINI Investigators:Differential effect ofβ-blocker therapy on insulin resistance as a function of insulin sensitizer use:results from GEMINI. Diabet Med 24:759-763, 2007
38) Kveiborg B, Christiansen B, Major-Petersen A et al:Metabolic effects ofβ-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs 6:209-217, 2006
39) Lardoux H, Gerard J, Blazquez G et al:Which β-blocker in pregnancy-induced hypertension? Lancet ii:1194, 1983
40) Magee LA, Duley L:Oralβ-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev, CDOO2863, 2003
41) Montan S:Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol 16:111-115, 2004
P.179 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009
2) Chobanian AV, Bakris GL, Black HR et al ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee:The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003
3) Ejima Y, Hasegawa Y, Sanada S et al:Characteristics of young-onset hypertension identified by targeted screening performed at a university health check-up. Hypertens Res 29:261-267, 2006
6) 松下啓, 梅村敏:若年者高血圧の治療. 日内会誌 92:227-233, 2003
7) Goldstein DS:Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5:86-99, 1983
8) Mancia G, de Baker G, Dominczak A et al:Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187, 2007
9) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
11) 守口篤, 荻原俊男:β遮断薬の降圧作用. β遮断薬のすべて (第2版), 先端医学社, 東京, 2004, p.52-p.56
12) Kaplan NM, Lieberman E:Treatment of hypertension. In:Drug therapy, Clinical Hypertension 4th Edition, Williams & Wilkins, Baltimore, 1986, p.180-p.272
13) Buhler FR, Burkart F, Lutold BE et al:Antihypertensive beta blocking action as related to renin and age:a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 36:653-669, 1975
P.184 掲載の参考文献
1) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255-3264, 1991
2) Dahlof B, Lindholm L, Hansson L:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
3) MRC working party:Medical Research Council trial of treatment of hypertension in older adults:principal results. BMJ 304:405-412, 1992
5) National Collaborating Centre for Chronic Conditions:Hypertension:management of hypertension in adults in primary care:partial update, Royal College of Physicians, London, 2006, p.1-p.94
6) Khan NA, Hemmelgarn B, Padwal R et al:The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension:Part 2-therapy. Can J Cardiol 23:539-550, 2007
7) Morgan TO, Anderson AI, Maclnnis RJ:ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 14:241-247, 2001
8) Messerli FH, Grossman E, Golgbourt U:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998.
11) Lindholm LH, Carlberg B, Samuelsson O:Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005
13) Bangalore S, Sawhney S, Messerli FH:Relation of β-blocker induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52:1482-1489, 2008
14) Kahn N, McAlister FA:Re-examining the efficacy of β-blockers for the treatment of hypertension:a meta-analysis. Can Med Assoc J 174:1737-1742, 2006
15) Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003
20) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン 2009, 日本高血圧学会, 東京, 2009
P.189 掲載の参考文献
1) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) . Lancet 338:1281-1285, 1991
2) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
3) Pepine CJ, Handberg EM, Cooper-DeHoff RM et al:A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST):a randomized controlled trial. JAMA 290:2805-2816, 2003
4) Turnbull F ; Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of different bloodpressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535, 2003
5) Dahlof B, Devereux RB, Kjeldsen SE et al:LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
6) Dahlof B, Sever PS, Poulter NR et al ; ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
7) Mancia G, de Backer G, Dominiczak A et al ; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology:2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 25:1105-1187, 2007
8) Bakris GL, Fonseca V, Katholi RE et al ; GEMINI Investigators:Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:arandomized controlled trial. JAMA 292:2227-2236, 2004
9) Bakris GL, Fonseca V, Katholi RE et al ; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
10) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009
11) Davies RF, Habibi H, Klinke WP et al; Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators:Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 25:619-625, 1995
P.195 掲載の参考文献
5) Panza JA, Epstein SE, Quyyumi AA:Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity. N Engl J Med 325:986-990, 1991
7) Opie LH, Gersh BJ et al:Drugs for the Heart 6th ed, WB Saunders Co, 2004
8) 山田裕一, 西村重敬:病態に応じた循環器薬の使い方 β遮断薬:心筋梗塞, 狭心症における使い方. medicina 43:1520-1522, 2006
9) Soucek M, Rihacek I, Frana P:Acomparison of the trough-to-peak ratio of cardio-selective β-blockers in patients with newly diagnosed hypertension. Blood Press Monit 11:337-342, 2006
11) Bang LE, Wiinberg N, Wachtell K et al:Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. Blood Press 16:392-397, 2007
12) Sarafidis P, Bogojevic Z, Basta E et al:Comparative efficacy of two different β-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich) 10:112-118, 2008
14) Kario K, Matsui Y, Shibasaki S et al; Japan Morning Surge-1 (JMS-1) Study Group:An α-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension:the Japan Morning Surge-1 Study. J Hypertens 26:1257-1265, 2008
15) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血. 圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009
16) Mancia G, De Backer G, Dominiczak A et al; Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC):2007 Guidelines for the management of arterial hypertension. Eur Heart J 28:1462-1536, 2007

Part 7 合併症を伴った高血圧とβ遮断薬の臨床応用を探る

P.201 掲載の参考文献
1) Lewington S, Clarke R, Qizilbash N et al:Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002
7) Hasebe N, Kido S, Ido A et al ; Angiographical Study in Angina with Hypertension Induced Insults (ASAHI) Investigators:Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res 25:381-387, 2002
8) Messerli FH, Mancia G, Conti CR et al:Dogma disputed:can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884-893, 2006
9) Mancia G, De Backer G, Dominiczak A et al:2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . Eur Heart J 28:1462-1536, 2007
12) First International Study of Infarct Survival Collaborative Group:Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction:ISIS-1. Lancet II:57-66, 1986
13) Viscoli CM, Horwitz RI, Singer BH:β-Blockers after myocardial infarction:influence of first-year clinical course on long-term effectiveness. Ann Intern Med 118:99-105, 1993
14) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with leftventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
15) Japanese β-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators:Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93:969-973, 2004
16) Gillman MW, Kannel WB, Belanger A et al:Influence of heart rate on mortality among persons with hypertension:the Framingham Study. Am Heart J 125:1148-1154, 1993
P.207 掲載の参考文献
1) Esler M:The sympathetic system and hypertension. Am J Hypertens 13 (suppl 1):S99-SI05, 2000
2) Singh BN, Courtney KR . Classification of antiarrhythmic mechanisms of drug action:experimental and clinical considerations. In:Cardiac Electrophysiology:From Cell to Bedside, eds by Zipes DP, Jalife J, W B Saunders Co, Philadelphia, 1990, p.882-p.897
6) Inoue H, Fujiki A, Origasa H et al:Prevalence of atrial fibrillation in the general population of Japan:an analysis based on periodic health examination. Int J Cardiol, 2008, in press
7) 不整脈薬物療法研究会:心房細動と血栓塞栓症:多施設共同調査. J Cardiol 31:227-238, 1998
9) Benjamin EJ, Levy D, Vaziri SM et al:Independent risk factors for atrial fibrillation in a population based cohort. The Framingham Heart Study. JAMA 271:840-844, 1994
10) Coumel P:Autonomic influence in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 7:999-1007, 1996
11) Okin PM, Devereux RB, Jern S et al ; Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study Investigators:Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol:the Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. Circulation 108:684-690, 2003
15) Why HJ, Richardson PJ:Effect of carvedilol on left ventricular function and mass in hypertension. J Cardiovasc Pharmacol 19 (Suppl 1):S50-S54, 1992
16) Nagele H, Bohlmann M, Eck U et al:Combination therapy with carvedilol and amiodarone in patients with severe heart failure. Eur/Heart Fail 2:71-79, 2000
17) McMurray J, Kober L, Robertson M et al:Antiarrhythmic effect of carvedilol after acute myocardial infarction:results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:525-530, 2005
18) Merritt JC, Niebauer M, Tarakji K et al:Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 92:735-736, 2003
20) van Gelder IC, Hagens VE, Bosker HA et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group:A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002
22) Bayes de Luna A, Coumel P, Leclercq JF et al:Ambulatory sudden cardiac death:mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117:151-159, 1989
23) Siegel D, Black DM, Seeley DG et al:Circadian variation in ventricular arrhythmias in hypertensive men. Am J Cardiol 69:344-347, 1992
P.215 掲載の参考文献
2) Boivin V, Jahns R, Gambaryan S et al:Immunofluorescent imaging of β1-and β2-adrenergic receptors in rat kidney. Kidney Int 59:515-531, 2001
3) Salomonsson M, Brannstrom K, Arendshorst WJ:α1-Adrenoceptor subtypes in rat renal resistance vessels:in vivo and in vitro studies. Am J Physiol Renal Physiol 278:F138-F147, 2000
5) Denton KM, Shweta A, Anderson WP:Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 13:27-34, 2002
10) Ye S, Ozgur B, Campese VM:Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 51:722-727, 1997
12) Amann K, Rump LC, Simonaviciene A et al:Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11:1469-1478, 2000
14) Ecder T, Schrier RW:Hypertension in autosomaldominant polycystic kidney disease:early occurrence and unique aspects. J Am Soc Nephrol 12:194-200, 2001
17) Veelken R, Vogel EM, Hilgers K et al:Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 19:1371-1378, 2008
18) Amann K, Nichols C, Tornig J et al:Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11:1003-1011, 1996
21) Bakris GL:Role for β-blockers in the management of diabetic kidney disease. Am J Hypertens 16:S7-S12, 2003
24) Bakris GL, Fonseca V, Katholi RE et al:GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
25) Marchi F, Ciriello G:Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria:a multicenter, randomized, openlabel, controlled study versus atenolol. Adv Ther 12:212-221, 1995
26) Fassbinder W, Quarder O, Waltz A:Treatment with carvedilol is associated with a significant reduction in microalbuminuria:a multicentre randomised study. Int J Clin Pract 53:519-522, 1999
27) van den Branden C, Gabriels M, Vamecq J et al:Carvedilol protects against glomerulosclerosis in rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two β-blocking drugs, carvedilol and propanolol. Nephron 77:319-324, 1997
30) Ritz E, Rump LC:Do β-blockers combined with RAS inhibitors make sense after all to protect against renal injury?Curr Hypertens Rep 9:409-414, 2007
32) Cice G, Ferrara L, D'Andrea A et al:Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy:aprospective, placebocontrolled trial. J Am Coll Cardiol 41:1438-1444, 2003
P.223 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:臓器障害を合併する高血圧:1) 脳血管障害. 高血圧治療ガイドライン2004, 日本高血圧学会, 2004, p.35-p,38
2) Griffith DNW, James IM, Newbury PA et al:The effect of β-adrenergic receptor blocking drugs on cerebral blood flow. Br J Clin Pharmac 7:491-494, 1979
3) Globus M, Keren A, Eldad M et al:The effect of chronic propranolol therapy on regional cerebral blood flow in hypertensive patients. Stroke 14:964-967, 1983
4) Madsen PL, Vorstrup S, Schmidt JF et al:Effect of acute and prolonged treatment with propranolol on cerebral blood flow and cerebral oxygen metabolism in healthy volunteers. Eur J Clin Pharmacol 39:295-297, 1990
5) 小原克之, 小張昌宏, 野川茂ほか:脳血管障害患者における塩酸カルテオロールの脳血流に及ぼす影響. 脳卒中 17:130-136, 1995
6) 田川皓一, 飯野耕三:本態性高血圧症を有する慢性脳血管障害患者の脳血流に及ぼす塩酸カルテオロール (ミケラン(R)LA) の影響. 新薬と臨 45:171-181, 1997
8) Schmalbruch IK, Linde R, Paulson OB et al:Activation-induced resetting of cerebral metabolism and flow is abolished by β-adrenergic blockade with propranolol. Strohe 33:251-255, 2002
9) Coop J, Warrender TS:Randomized trial of treatment of hypertension in elderly patients in primary care. Br Med J 293:1145-1151 1986
10) Medical Research Council Working Party:MRC trial of treatment of mild hypertension:principal results. Br Med J 291:97-104, 1985
12) Wilkstrand J, Warnord I, Olsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988
13) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
14) Dahlof B, Devereux RB, Kjeldsen SE et al; LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 359:995-1003, 2002
16) Wiysonge CSU, Bradley HA, Mayosi BM et al:Beta-blockers for hypertension. Cochrane Database Syst Rev Issue l:Art No CD002003, 2007
17) Lindholm LH, Carlberg B, Samuelsson O:Should β blockers remain first choice in the treatment of primary hypertension?A meta-analysis. Lancet 366:1545-1553, 2005
19) Sacco RL, Adams R, Albers G et al:American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology:Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack:a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke:co-sponsored by the Council on Cardiovascular Radiology and Intervention:the American Academy of Neurology affirms the value of this guideline. Stroke 37:577-617, 2006
20) 日本高血圧学会高血圧治療ガイドライン作成委員会:臓器障害を合併する高血圧:1) 脳血管障害. 高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009, p.46-p.49
21) Broderick J, Connolly S, Feldmann E et al; American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group:Guidelines for the management of spontaneous intracerebral hemorrhage in adults:2007 update:a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38:2001-2023, 2007
22) The Dutch TIA trial Study Group:Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 24:543-548, 1993
23) Eriksson S, Olofsson B-O, Wester P-O; TEST study group:Atenolol in secondary prevention after stroke. Cerebrovasc Dis 5:21-25, 1995
24) PROGRESS Collaborative Group:Randomized trial of perindopril based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
25) Schrader J, Luders S, Kulschewski A et al; MOSES Study Group:Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention:principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218-1226, 2005
26) Yusuf S, Diener H-C, Sacco RL et al; PRoFESS Study Group:Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225-1237, 2008
29) Saviz SL, Erhardt JA, Anthony JV et al:The novel β-blocker, carvedilol, provides neuroprotection in transient focal stroke.J Cereb Blood Flow Metab 20:1197-1204, 2000
30) Hedbald B, Wikstrand J, Janzon L et al:Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness:main result from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103:1721-1726, 2001
P.229 掲載の参考文献
1) American Diabetes Association:Treatment of hypertension in adults with diabetes. Diabetes Care 25:199-201, 2002
2) Kosegawa I, Inaba M, Morita T et al:Effects of the vasodilatory β-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 20:751-761, 1998
3) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with two β-blocking agents on insulin sensitivity:the carvedilolmetoprorol study. J Hypertens 14:489-494, 1996
4) Giugliano D, Acampora R, Marfella R et al:Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126:955-959, 1997
6) Fonseca V, Bakris GL, Bell DSH et al:Differential effect of β-blocker therapy on insulin resistance as a function of insulin sensitizer use:results from GEMINI. Diabet Med 24:759-763, 2007
7) Shorr R, Ray WA, Daugherty JR et al:Antihypertensive and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278:40-43, 1997
9) UK Prospective Diabetes Study (UKPDS) Group:Efficacy of atenolol and captopril in reduction risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720, 1998
12) Kjekshus J, Gilpin E, Cali G et al:Diabetic patients and β-blockers after acute myocardial infarction. Eur Heart J 11:43-50, 1990
13) Joans M, Reicher-Reiss H, Boyko V et al:Usefulness of β-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am j Cardiol 77:1273-1277, 1996
8) UK Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
P.235 掲載の参考文献
1) Dahlof B, Devereux RB, Kjeldsen SE et al ; LIFE study group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
2) Dahlof B, Sever PS, Poulter NR et al ; ASCOT Investigators:Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial. Lancet 366:895-906, 2005
3) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009
4) 動脈硬化診療・疫学委員会:脂質異常症の診断基準. 動脈硬化性疾患予防ガイドライン2007年版, 日本動脈硬化学会, 東京, 2007, p.11-p.13
6) Oslund-Lindqvist AM, Lindqvist P, Brautigam J et al:The effect of metoprolol on diet-induced atherosclerosis in rabbits. Arteriosclerosis 8:40-45, 1988
8) Maggi E, Marchesi E, Covini D et al:Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 27:532-538, 1996
9) Amato M, Montorsi P, Ravani A et al:Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis:correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J 28:2094-2101, 2007
10) Hedblad B, Wikstrand J, Janzon L et al:Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness:main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) . Circulation 103:1721-1726, 2001
12) Sipahi I, Tuzcu EM, Wolski KE et al:β-blockers and progression of coronary atherosclerosis:pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 147:10-18, 2007
13) Bessho H, Suzuki J, Tobe A:Vascular effects of betaxolol, a cardioselective β-adrenoceptor antagonist in isolated rat arteries. Jpn J Pharmacol 55:351-358, 1991
14) Adachi T, Hori S, Miyazaki K et al:Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Eur J Pharmacol 286:201-204, 1995
15) Jayachandran M, Hayashi T, Sumi D et al:Up-regulation of endothelial nitric oxide synthase throughβ2-adrenergic receptor:the role ofβ-blocker with NO releasing action. Biochem Biophys Res Commun 280:589-594, 2001
16) Garlichs CD, Zhang H, MUgge A et al:Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur/Clin Invest 29:12-16, 1999
17) Ueshiba H, Yoshino G:Effects of celiprolol on insulin resistance and steroid hormones in essential hypertension. Ther Res 29:569-575, 2008
18) The β-Blocker Heart Attack Trial (BHAT) research group:A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707-1714, 1982
19) Wikstrand J, Warnold I, Tuomilehto J et al:Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17:579-588, 1991
P.241 掲載の参考文献
1) 宗像正徳:高血圧の成因としての神経心理的要因の重要性はどこまでわかったか?Med Pract 21:237-239, 2004
2) 宗像正徳:高血圧のコントロール-ストレスとの関連 総合臨 53:547-552, 2004
3) 河野雄平:災害と高血圧 血圧 8:873-877, 2001
4) 宗像正徳:ストレスと血圧の関係は?肥満と糖尿病 3:47-49, 2004
5) 宗像正徳:肉体的ストレスとその昇圧に対する治療戦略. 循環器 53:207-212, 2003
6) 宗像正徳:レニン・アンジオテンシン系と早朝高血圧. 呼と循 53:825-832, 2005
7) 宗像正徳:高血圧とストレスマネジメント. 総合臨 50:160-163, 2001
8) 宗像正徳, 布川徹, 吉永馨ほか:精神労働と血圧. 日災医会誌 46:290-295, 1998
10) Munakata M, Saito Y, Nunokawa T et al:Clinical significance of blood pressure response triggered by a doctor's visit in patients with essential hypertension. Hypertens Res 25:343-349, 2002
11) Mattews KA, Owens JF, Kulluer LH et al:Stress-induced pulse pressure change predicts women's carotid atherosclerosis. Stroke 29:1525-1530, 1998
12) 宗像正徳:高血圧における「うつ」と「不安」の臨床. 自律神経 44:83-88, 2007
13) 宗像正徳:8. ハードな仕事は血圧も上げる? (ストレスによる高血圧) . シミュレイション内科高血圧を探る, 島田和幸編, 永井書店, 大阪, 2004, p.143-p.147
14) Schnall PL, Pieper C, Schwartz JE et al:The relationship between 'job strain,' workplace diastolic blood pressure, and left ventricular mass index. Results of a case-control study. JAMA 263:1929-1935, 1990
15) Parati G, Pomidossi G, Albini F et al:Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 5:93-98, 1987
19) 宗像正徳, 布川徹, 伊藤信彦ほか:降圧治療の心理, 行動特性に及ぼす影響. 日職災医会誌 49:460-464, 2001

Part 8 虚血性心疾患治療薬としてのβ遮断薬の有用性をみる

P.249 掲載の参考文献
2) Miyashiro JK, Feigl EO:Feedforward control of coronary blood flow via coronary beta-receptor stimulation. Circ Res 73:252-263, 1993
5) Kuo L, Chancellor JD:Adenosine potentiates flow-induced dilation of coronary arterioles by activating KATP channels in endothelium. Am J Physiol Heart Circ Physiol 269:H541-H549, 1995
6) Gauthier C, Leblais V, Kobzik L et al:The negative inotropic effect of β3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Ivest 102:1377-1384, 1998
7) Varghese P, Harrison RW, Lofthouse RA et al:β3-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 106:697-703, 2000
9) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blockers:importance of ancillary properties. 1) Prog Cardiovasc Dis 39:445-456, 1997
10) Asanuma H, Node K, Minamino T et al:Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol 41:499-505, 2003
11) Gao F, Chen J, Lopez BL et al:Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 406:109-116, 2000
12) Asanuma H Minam010 T, Sanada S et al:β-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation 109:2773-2779, 2004
13) Antman EM, Anbe DT, Armstrong PW et al:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction) . J Am Coll Cardiol 44:e1-e211, 2004
15) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
16) Pristipino C, Beltrame JF, Finocchiaro ML et al:Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circarlation 101:1102-1108, 2000
17) Japanese β-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators:Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93:969-973, 2004
P.253 掲載の参考文献
1) First International Study of Infarct Survival Collaborative Group:Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction:ISIS-1. Lancet ii:57-66, 1986
3) Roberts R, Rogers WJ, Mueller HS et a l:Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83:422-437, 1991
4) 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 8:Stabilization of the patient with acute coronary syndromes. Circulation 112 (24 Suppl):IV89-IV110, 2005
5) Freemantle N, Cleland J, Young P et al:βBlockade after myocardial infarction:systematic review and meta regression analysis. BMI 318:1730-1737, 1999
6) Chen ZM, Pan HC, Chen YP et al:COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group:Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial. Lancet 366:1622-1632, 2005
8) 第3章 CCUの診療. CCUマニュアル, 国立循環器病センターレジデント編 中外医学社, 東京, 2000
P.260 掲載の参考文献
1) Chadda K, Goldstein S, Byington R et al:Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 3:503-510, 1986
2) Akiyama T, Pawitan Y, Greenberg H et al; CAST Investigators:Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 68:1551-1555, 1991
4) Clausen T, Flatman JA:β2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. Br J Pharmacol 68:749-755, 1980
5) Brown MJ, Brown DC, Murphy MB:Hypokalemia from β2-receptor stimulation by circulating epinephrine. N Engl J Med 309:1414-1419, 1983
7) Dargie HJ:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
8) McMurray J, Kober L, Robertson M et al:Antiarrhythmic effect of carvedilol after acute myocardial infarction:results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45:525-530, 2005
15) Murray DR, Prabhu SD, Chandrasekar B:Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101:2338-2341, 2000
17) Tsutamoto T, Wada A, Maeda K et al:Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure:prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96:509-516, 1997
19) Ogawa H, Yasue H:Comparison of the effects of beta-blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese. Jpn Circ J 67 (Supple I):15, 2003
21) Naito K, Anzai T, Yoshikawa T et al:Impact of chronic kidney disease on postinfarction inflammation, oxidative stress and left ventricular remodeling. J Card Fail 14:831-838, 2008
22) Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators:Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
24) Cice G, Ferrara L, D'Andrea A et al:Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy:aprospective, placebocontrolled trial. J Am Coll Cardiol 41:1438-1444, 2003
P.265 掲載の参考文献
2) van de Ven LLM, Vermeulen A, Tans JGM et al:Which drug to choose for stable angina pectoris:a comparative study between bisoprolol and nitrates. Int J Cardiol 47:217-223, 1995
3) de Vries RJ, van den Heuvel AF, Lok DJ et al; Netherlands Working Group on Cardiovascular Research (WCN):Nifedipine gastrointestinal therapeutic system versus atenorol in stable angina pectoris. Int J Cardiol 57:143-150, 1996
4) Fox KM, Mulcahy D, Findlay I et al; The TIBET Study Group:The Total Ischemic Burden European Trial (TIBET) . Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 17:96-103, 1996
5) Prida XE, Hill JA, Feldman RL:Systemic and coronary hemodynamic effects of combined α-and β-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am J Cardiol 59:1084-1088, 1987
6) 加藤和三, 飯沼宏之, 稲垣義明ほか.:血管拡張作用を有するβ遮断薬 carvedilol (DQ-2466) の狭心症に対する臨床効果-Atenolol を対象とした二重盲検比較試験-. 臨と研 67:280-293, 1996
7) The Japanese β-blockers and Calcium antagonists Myocardial Infarction JBCMI) Investigators:Comparison of the effect β blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93
P.269 掲載の参考文献
1) Cohn PF:Severe asymptomatic coronary artery disease:a diagnostic, prognostic and therapeutic puzzle. Am J Med 62:565-568, 1977
2) 戸嶋裕徳, 村山正博, 岸田浩ほか:本邦における無症候性心筋虚血の実態. 心臓 27:87-95, 1995
3) 津谷裕之, 三浦博:無症候性心筋虚血の病型別臨床と発生頻度および予後. 日臨 61 [増刊号5:冠動脈の臨床 (下) ]:613-620, 2003
4) Muller JE, Tofler GH, Stone PH:Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79:733-743, 1989
5) von Arnim T; The TIBBS Investigators:Medical treatment to reduce total ischemic burden:total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 25:231-238, 1995
8) Frishman WH, Glasser S, Stone P et al:Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 83:507-514, 1999
9) Davies RF, Habibi H, Klinke WP et al; Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators:Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 25:619-625, 1995
10) Savonitto S, Ardissiono D, Egstrup K et al:Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 27:311-316, 1996
12) Pepine CJ, Cohn PF, Deedwania PC et al:Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life:the Atenolol Silent Ischemia Study (ASIST) . Circulation 90:762-768, 1994
13) von Arnim T; TIBBS Investigators:Prognostic significance of transient ischemic episodes:response to treatment shows improved prognosis:results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 28:20-24, 1996
14) Rehnqvist N, Hjemdahl P, Billing E et al:Effects of metoprolol vs verapamil in patients with stable angina pectoris:the Angina Prognosis Study in Stockholm (APSIS) . Eur Heart J 17:76-81, 1996